Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

Six months Six months ended ended Jun 30, 2009 Jun 30, 2008 ---------------------------- Stock-based compensation $ (592) $ (924) Termination and reorganization costs (1,266) (2,755) Litigation expenses (2,241) (2,289) Non-recurring transaction fees, and supply/distribution agreement termination costs (1,032) (751) --------------------------------------------------------------------- $ (5,131) $ (6,718) ---------------------------- e. Amortization of acquisition related intangible assets and medical technologies. f. Non-recurring in-process research and development expense relating to payments made to licensors and collaborators. g. Foreign exchange fluctuations on foreign currency net monetary assets. h. Loss on write-down of deferred financing charges and realized loss on disposition of capital assets. i. Loss on write-down of investments related to two available-for-sale equity securities that had been trading below carrying value for a prolonged period of time. j. Amortization of deferred financing costs. k. Tax effects of adjustments a. through j. for the period. ANGIOTECH PHARMARCEUTICALS, INC. CALCULATION OF ADJUSTED EBITDA (unaudited) Three months Six months (in thousands ended June 30, ended Jun
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) — ... online medical bill review and advocacy service, has signed ... FREE WellCard Savings discount health services marketplace. ... was more than they expected to pay. As part ... care costs, WellCard Savings is pleased to offer medical ...
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
(Date:12/19/2014)... Calif. , Dec. 19, 2014  Roche (SIX: ... of Bina Technologies, Inc. (Bina), a privately held ... , USA. Bina provides a big data ... generation sequencing (NGS) data. Bina,s proprietary on-market Genomic ... and academic researchers to perform fast and scalable ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... 1 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO ... a conference call and webcast on Friday, October 2, ... update investors on the Company,s Phase 3 program for ... dial 1-416-644-3426 or 1-800-732-1073. A live audio webcast will ...
... Enerkem,s future biofuels plant will supply green energy to ... - Enerkem, a leading waste-to-biofuels and green chemicals technology company, ... that will heat a Strathcona County neighbourhood, using the residual ... Edmonton waste-to-biofuels plant. , The project received grant funding in ...
... YORK, Oct. 1 /PRNewswire-FirstCall/ - Healthnostics, Inc. (OTC PK: ... its strategy for the biomedical content layer of the ... major shift in strategy by MedBioWorld.com will consist of ... professional base to a wider, more general audience. This ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Phase 3 Update Conference Call 2Enerkem Announces Unique Community Energy Project 2Healthnostics Unveils Biomedical Content Strategy for Medbioworld.com 2
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... renowned climate researcher Caroline Leck of Stockholm University has ... results are truly sensational," says Dr Leck. "If confirmed ... efforts to achieve the political targets for climate." ... Earth,s mean surface temperature climbed sharply through the 1990s, ...
... one of the leaders in the field of neurosciences, ... of one of literature,s greatest authors, Virginia Woolf. The ... the literature she wrote and comments, letters and other ... medical status. The author uses current insights into depression, ...
... 25, 2013 /PRNewswire-iReach/ --   Find Heather on ... . She is a a third year physics major at the ... also learned after writing numerous twenty plus page lab reports, a life ... a career relating to patents and IP law. Last summer, she interned ...
Cached Biology News:Global warming less extreme than feared? 2Global warming less extreme than feared? 3Global warming less extreme than feared? 4The Website You Have to Log Into 2The Website You Have to Log Into 3
Recombinant Rhesus Monkey IFN-Alpha...
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
Biology Products: